Leerink Swann Upgrades Amicus Therapeutics (FOLD) to Outperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/12/2026
- S&P 500 rises as CoreWeave results fuel AI optimism
- Oil prices edge up as investors weigh US-Iran talks deadlock against lower demand
- CoreWeave soars after fifth straight quarter of record revenue, raised guide
- Four key things investors will watch in Nvidia's earnings next week
- Silver could surge to $90 as investment demand takes over, Citi says
- Lumentum Holdings (LITE) Tops Q4 EPS by 28c, Beats on Revenue; Offers Q1 Guidance
- Crude Inventory Rose 17.2 Million Barrels Last Week - EIA
- Aurora Cannabis rejects Curaleaf's unsolicited $4-per-share takeover bid
- AbCellera Biologics (ABCL) PT Raised to $30 at Truist on 'best-in-class potential'
- Comscore plans restructuring with $20M-$25M in cost cuts
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
- After-Hours Movers: SPCX, AMD, ANET, PINS, APPS, UPST, ZETA, BKNG, LCID, CPNG, MTCH
Janney Upgrades Amicus Therapeutics (FOLD) to Buy
July 1, 2014 6:53 AM EDTJanney Montgomery Scott upgraded Amicus Therapeutics (NASDAQ: FOLD) from Neutral to Buy with a price target of $5.00 (from $2.50).
For an analyst ratings summary and ratings history on Amicus Therapeutics click here. For more ratings news on Amicus Therapeutics click here.
Shares of Amicus Therapeutics closed at $3.34 yesterday.
... MoreAmicus Therapeutics (FOLD) Moves Higher on Volume
June 30, 2014 11:52 AM EDTAmicus Therapeutics (NASDAQ: FOLD) moving to the highs of the session on volume. Shares up 28.7%.
This morning, the company provided... More
Amicus Therapeutics (FOLD) Updates on Migalastat Phase 3; Top-Line Data Expected in Q314
June 30, 2014 7:06 AM EDTAmicus Therapeutics (Nasdaq: FOLD) has provided updates and detailed the statistical analysis plan for its second Phase 3 study (Study 012) of the oral small molecule pharmacological chaperone migalastat HCl ("migalastat") monotherapy for Fabry patients with amenable mutations. The 18-month primary treatment period is now complete and top-line data from Study 012 are expected in the third quarter of 2014. If successful, Study 012 will trigger the process for European regulatory approval of migalastat as a monotherapy for Fabry patients with amenable mutations.
Study 012 is the first clinical study to compare oral migalastat to standard-of-care enzyme replacement therapies (ERTs)... More
